The deadline for entering the 2020 PharmaTimes Communications Awards, Sales Awards and Marketer of the Year competitions has been extended to Friday October 2 after a last-minute spike in enquiries
News
IVD industry must be supported in COVID-19 recovery strategy, says BIVDA
Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma
Over half of patients treated with combination therapy were alive and relapse-free after five years
AZ picks up oral PCSK9 inhibitor programme from Dogma
AZ will take the programme forward into clinical development
Lilly’s COVID-19 antibody shows promise in mid-stage study
Middle dose tested hit the primary endpoint of the Phase II trial
Sleep apnoea linked to poorer outcomes from COVID-19, study finds
People with sleep condition could be at an increased risk of adverse outcomes from COVID-19
ICR study combines precision medicines to treat drug-resistant cancers
Researchers found combination treatment showed promise against a range of cancer types
GenSight Biologics seeks EU approval for gene therapy
Lumevoq is designed to treat vision loss associated with Leber Hereditary Optic Neuropathy
NICE unites with global health leaders to highlight evidence-based healthcare
World Evidence-based Healthcare Day takes place on 20 October
A third of UK doctors have treated COVID-19 patients without full PPE, report finds
Report also highlights the impact of COVID-19 on the physical and mental health of doctors
Joint letter implores government to allow pharmacists to alter prescriptions
Pharmacists, GPs and patients join arms to call for law change
MSD partners with Seattle Genetics on two new oncology projects
Agreement grants MSD access to investigational ADC and a small molecule tyrosine kinase inhibitor
Shionogi launches novel antibiotic Fetcroja in the UK
The drug is indicated for use as a treatment of infections caused by aerobic Gram-negative bacteria
NICE backing for AZ’ Tagrisso
The Institute has endorsed the drug for first-line treatment of adults with locally-advanced or EGFR mutation-positive NSCLC
AZ resumes trial of COVID-19 vaccine
The move follows a green light by the UK’s MHRA
